HTG Molecular Diagnostics to Participate in the Cantor Fitzgerald Oncology, Hematology & HemeOnc Conference
HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) will participate in the Cantor Fitzgerald Oncology, Hematology & HemeOnc Conference in New York City on September 28, 2022.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) will participate in the Cantor Fitzgerald Oncology, Hematology & HemeOnc Conference in New York City on September 28, 2022. CEO John Lubniewski will join the panel discussion titled “Predictive Biomarkers, Sequencing and Diagnostics, Oh My!” at 9:50 am ET. HTG focuses on advancing precision medicine through transcriptome-wide profiling technology, enhancing diagnostic tools, and supporting drug discovery across various diseases. For additional inquiries or meetings, attendees should contact their Cantor Fitzgerald sales representative.
Details
News Market Reaction – HTGM
The recorded move for HTGM in the trading session of this news was -1.93%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
TUCSON, Ariz., Sept. 26, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, today announced that management will participate in the Cantor Fitzgerald Oncology, Hematology & HemeOnc Conference at the Lotte New York Palace in New York City on Wednesday, September 28, 2022.
John Lubniewski, HTG CEO will be a participant in the panel discussion, “Predictive Biomarkers, Sequencing and Diagnostics, Oh My!” at 9:50 am ET on September 28, 2022.
For more information or to schedule a one-on-one meeting with management, please contact your Cantor Fitzgerald sales representative.
About HTG:
HTG is accelerating precision medicine from diagnosis to treatment by harnessing the power of transcriptome-wide profiling to drive translational research, novel therapeutics and clinical diagnostics across a variety of disease areas.
Building on more than a decade of pioneering innovation and partnerships with biopharma leaders and major academic institutes, HTG’s proprietary RNA platform technologies are designed to make the development of life science tools and diagnostics more effective and efficient and to unlock a differentiated and disruptive approach to transformative drug discovery. For more information visit www.htgmolecular.com.
HTG Investor Contact:
Ashley Robinson
LifeSci Advisors
Phone: (617) 430-7577
Email: arr@lifesciadvisors.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.